Table 1 Baseline characteristics of study subjects
Characteristics | Patients (n = 225) |
|---|---|
Age (years), mean (SD) | 63.2 (6.1) |
Pre-op PSA (ng/mL), mean (SD) | 12.8 (15.5) |
Clinical tumor stage, n (%) | |
T1 | 73 (32.5) |
T2 | 142 (63.1) |
T3 | 5 (2.2) |
NA | 5 (2.2) |
Gleason score, n (%) | |
≤6 | 92 (40.9) |
7 | 93 (41.3) |
≥8 | 40 (17.8) |
Pathological stage, n (%) | |
pT2a | 7 (3.1) |
pT2b | 3 (1.3) |
pT2c | 60 (26.7) |
pT3a | 100 (44.4) |
pT3b | 55 (24.4) |
Margin status, n (%) | |
0 (negative) | 71 (31.6) |
1 (positive) | 154 (68.4) |
Nodal status, n (%) | |
N0 | 186 (82.7) |
N1 | 39 (17.3) |
High risk score (pT3N + M+), n (%) | |
0 | 32 (14.2) |
1 | 192 (85.8) |
NA | 1 (0.0) |
Biochemical recurrence, n (%) | |
No | 119 (52.9) |
Yes | 106 (47.1) |
Death by prostate cancer, n (%) | |
No | 215 (95.6)) |
Yes | 10 (4.4) |
Death by other causes, n (%) | |
No | 191 (84.9)) |
Yes | 34 (15.1) |
Death – all causes, n (%) | |
No | 181 (80.4) |
Yes | 44 (19.6) |
Time to BCR (years), mean (SD) | 6.8 (4.5) |
Time to DPCa (years), mean (SD) | 10.6 (3.1) |